Real‐world resource use and costs of haemophilia A‐related bleeding
- 2 June 2017
- journal article
- Published by Wiley in Haemophilia
- Vol. 23 (4), e267-e275
- https://doi.org/10.1111/hae.13220
Abstract
Prophylaxis treatment is recommended for haemophilia patients, but associated real-world economic costs and potential cost-savings associated with improved disease management are not fully known. This study aimed to assess haemophilia A-related resource use and cost by treatment type (prophylaxis versus non-prophylaxis) and any associated cost-savings. Truven MarketScan Commercial claims data (2004–2012) were used to identify haemophilia A-related healthcare utilization, healthcare costs and patterns of prophylaxis and non-prophylaxis treatment among 6- to 64-year-old males. We estimated bleeding-related resource utilization and costs in three age groups (6–18, 19–44, 45–64) by treatment types and assessed the extent to which early initiation of prophylactic treatment can mitigate them. T-tests and ordinary least squares regressions were used to compare unadjusted and demographics-adjusted cost estimates. Among children, overall haemophilia- and bleeding-related non-pharmacy costs were substantially lower for patients receiving prophylaxis (haemophilia-related: $15,864 vs. $53,408; P < 0.001; bleeding-related: $696 vs. $2013, respectively; P = 0.04). Among younger adults (19–44), haemophilia-related non-pharmacy costs were lower for patients receiving prophylaxis ($22,028 vs. $56,311, respectively; P = 0.001). Among children, these savings fully offset the incremental pharmacy cost due to prophylaxis. Among younger adults, the savings offset approximately 34% of the incremental pharmacy cost. No differences were found for older adults (45–64). These results suggest that initiating prophylaxis earlier in life may reduce the healthcare costs of bleeding events and their long-term complications. Future studies should strive to collect more detailed information on disease severity and treatment protocols to improve estimates of disease burden.Keywords
Funding Information
- Biogen
This publication has 20 references indexed in Scilit:
- Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN studyHaemophilia, 2013
- Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial FibrillationCardiology Research and Practice, 2012
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or BCochrane Database of Systematic Reviews, 2011
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)Journal of Thrombosis and Haemostasis, 2011
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- The Validity and Reliability of Maternal Recall of Breastfeeding PracticeNutrition Reviews, 2005
- Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcomeHaemophilia, 2002
- Haemophilia prophylaxis in young patients–a long‐term follow‐upJournal of Internal Medicine, 1997
- The Reliability of Recall Data: a Literature ReviewBulletin of Sociological Methodology/Bulletin de Méthodologie Sociologique, 1995